Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07370649

Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study

This study evaluates the real-world effectiveness and safety of a long-acting injectable HIV treatment consisting of cabotegravir and rilpivirine in people living with HIV-1. The focus is on individuals with HIV-1 subtype A6, which is common in Eastern Europe and among people who acquired HIV in that region, and on comparison with individuals with subtype B and those with an unknown subtype.

Although long-acting cabotegravir and rilpivirine are widely used and effective, limited real-world data are available on how well this treatment works in people with HIV-1 subtype A6. This is important because subtype A6 has been suggested as a potential risk factor for treatment failure, but current evidence is inconclusive.

The study uses existing medical records from treatment centers in Poland, Germany, and the Czech Republic. It includes adults with HIV who have received at least one injection of long-acting cabotegravir and rilpivirine and follows their clinical outcomes for up to 24 months. Researchers will assess viral suppression, treatment persistence, adherence to injection schedules, and reasons for treatment discontinuation.

The results of this study will help clinicians better understand whether HIV-1 subtype A6 affects treatment outcomes and whether knowing a patient's HIV subtype is important when deciding to switch to long-acting injectable therapy. The findings may support safer and more effective use of this treatment in diverse patient populations.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Human Immunodeficiency Virus (HIV)-1 Infection Acquired Immunodeficiency Syndrome Blood-Borne Infections Communicable Diseases Genital Diseases HIV Infections HIV-1 Subtype A6 Infection HIV-1 Subtype B Infection Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Slow Virus Diseases Urogenital Diseases Virologically Suppressed HIV-1 Infection Receiving Long-Acting Antiretroviral Therapy Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Na Bulovce Praque HIV Centre, Department of Infectious Diseases, Prague, Czechia

Loading trial locations.

About this study

This is a multicentre, international, real-world, retrospective observational study designed to evaluate clinical outcomes of long-acting injectable cabotegravir plus rilpivirine (CAB/RPV LA) in adults living with HIV-1. The study is conducted at HIV treatment centers in Poland, Germany, and the Czech Republic and is based on routinely collected clinical data from electronic medical records and paper charts.

The study population includes treatment-experienced individuals aged 18 years or older who received at least one dose of CAB/RPV LA in routine clinical practice. Participants are grouped according to HIV-1 subtype: subtype A6, subtype B, and unknown subtype. Individuals with known subtype A6 are matched with individuals with subtype B using propensity score matching to reduce the impact of confounding factors. Participants with unknown subtype are analyzed as an unmatched group.

Clinical data are collected from the time of CAB/RPV LA initiation (index date) and from follow-up visits closest to 6, 12, 18, and 24 months after initiation. Outcomes assessed include treatment persistence, adherence to injection schedules, discontinuation rates and reasons for discontinuation, and measures of virologic effectiveness. Virologic outcomes include viral suppression, viral rebound, and confirmed virologic failure as defined by standard HIV RNA criteria.

For participants with unknown HIV-1 subtype, proviral DNA genotyping is performed after initial descriptive analyses to explore whether knowledge of HIV-1 subtype has prognostic relevance for clinical outcomes. Genotypic data are analyzed descriptively and may inform additional exploratory analyses.

As this is a retrospective, non-interventional study using existing clinical data, no study-specific treatment interventions are performed. Safety data collection is limited to adverse events leading to treatment discontinuation, reflecting routine clinical practice. The study aims to provide clinically relevant real-world evidence on the use of CAB/RPV LA across different HIV-1 subtypes, with particular focus on subtype A6.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed diagnosis of HIV-1 infection
  • Age ≥18 years at the time of initiation of long-acting cabotegravir plus rilpivirine (CAB/RPV LA)
  • Received at least one dose of CAB/RPV LA as part of routine clinical care
  • Availability of relevant clinical data in medical records for retrospective analysis
  • Signed informed consent for use of clinical data
  • Agreement to provide an additional blood sample for proviral DNA genotyping, if HIV-1 subtype was unknown at treatment initiation

Exclusion criteria

  • Lack of patient consent for use of clinical data for research purposes

Treatment and study plan

Cabotegravir Plus Rilpivirine Long-Acting Injectable

Drug

Cabotegravir plus rilpivirine long-acting (CAB/RPV LA) is a complete antiretroviral regimen administered as intramuscular injections and approved for the maintenance treatment of HIV-1 infection in adults. In this observational, retrospective study, CAB/RPV LA is used as part of routine clinical care and is not assigned by the study protocol. Participants received CAB/RPV LA according to local prescribing information, including dosing intervals and injection windows.

The study evaluates real-world clinical outcomes of CAB/RPV LA across different HIV-1 subtype groups (subtype A6, subtype B, and unknown subtype). Outcomes of interest include virologic effectiveness, treatment persistence, adherence to injection schedules, and treatment discontinuation. No study-specific modifications to dosing, administration, or clinical management are performed.

Other names: CAB/RPV LA, Long-Acting Cabotegravir and Rilpivirine, Cabotegravir + Rilpivirine

Primary outcomes

  1. Virologic Suppression at Follow-Up

    Time frame: Up to 24 months after initiation of CAB/RPV LA

    Proportion of participants with HIV-1 RNA viral load <50 copies/mL at follow-up after initiation of long-acting cabotegravir plus rilpivirine (CAB/RPV LA), assessed using available clinical laboratory measurements. Virologic suppression will be evaluated at approximately 6, 12, 18, and 24 months after treatment initiation, with last observation carried forward where applicable.

Secondary outcomes

  1. Treatment Persistence on CAB/RPV LA

    Time frame: Up to 24 months after initiation of CAB/RPV LA

    Proportion of participants who remain on long-acting cabotegravir plus rilpivirine (CAB/RPV LA) at each follow-up time point after initiation, based on documentation of continued injections in routine clinical care.

  2. Treatment Discontinuation Rate

    Time frame: Up to 24 months after initiation of CAB/RPV LA

    Proportion of participants who discontinue CAB/RPV LA after initiation, including documentation of the reason for discontinuation such as adverse events, virologic failure, or other clinical or patient-related reasons.

  3. Time to Treatment Discontinuation

    Time frame: Up to 24 months after initiation of CAB/RPV LA

    Median time from first administration of CAB/RPV LA to permanent discontinuation of the regimen, calculated using available clinical records.

  4. Adherence to Injection Schedule

    Time frame: Up to 24 months after initiation of CAB/RPV LA

    Adherence to the CAB/RPV LA dosing schedule, assessed as the proportion of participants receiving injections within the allowed ±7-day dosing window relative to the target injection date.

  5. Delayed or Missed Injections

    Time frame: Up to 24 months after initiation of CAB/RPV LA

    Proportion of participants with delayed injections (>7 days after target date), missed injections, and the number and duration of delayed or missed injections during follow-up.

  6. Confirmed Virologic Failure (CVF)

    Time frame: Up to 24 months after initiation of CAB/RPV LA

    Proportion of participants meeting criteria for confirmed virologic failure, defined as two consecutive HIV-1 RNA measurements ≥200 copies/mL, or one HIV-1 RNA ≥200 copies/mL followed by treatment discontinuation within four months.

  7. Viral Rebound

    Time frame: Up to 24 months after initiation of CAB/RPV LA

    Proportion of participants experiencing viral rebound, including viral blips (single HIV-1 RNA 50-199 copies/mL followed by <50 copies/mL), low-level viremia (two consecutive measurements 50-199 copies/mL), or viremia >200 copies/mL not leading to treatment discontinuation.

  8. Virologic Non-Response After CVF

    Time frame: Up to 24 months after initiation of CAB/RPV LA

    Proportion of participants who do not achieve re-suppression (HIV-1 RNA <50 copies/mL) following confirmed virologic failure during the follow-up period.

Study contacts

Contact information is provided by the study sponsor or research team.

Karolina Sorbian-Gajewska

CONTACT

Miłosz Parczewski, prof. dr hab. n. med.

CONTACT

[email protected]

+48 91 813 94 41

Sponsors and collaborators

Lead sponsor

Pomeranian Medical University Szczecin

Other

Collaborators

  • ViiV Healthcare

Registry information

Official study title

Long-Acting Cabotegravir And Rilipivirine In People Living With HIV-1 Subtype A6. A Multicentre Real-world, Retrospective Matched Case Study

Acronym: LACRIS

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 27, 2026
Registry last updated
Jun 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.